TR&D1: Development of Improved DNP Methodology and HP MR Acquisition Techniques

TR

• 批准号: 9324237
• 负责人: Daniel B Vigneron
• 金额: $ 38.51万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-01 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9324237
• 关键词: Advisory Committees; Animal Model; Animals; Base Sequence; Bioreactors; Brain; Carbon; Clinical Research; Clinical Trials; Collaborations; Communities; Computer software; Data; Development; Devices; Electromagnetics; Equipment; Extramural Activities; Faculty; Feedback; Frequencies; Funding; Future; Goals; Grant; Hand; Head; Housing; Human; Human Resources; Imaging Techniques; Investigation; Lasers; Liquid substance; Magnetic Resonance Imaging; Metastatic Neoplasm to the Liver; Metastatic Prostate Cancer; Methodology; Methods; Nuclear; Patients; Performance; Phase I Clinical Trials; Plasticizers; Preclinical Testing; Process; RF coil; Reproducibility; Research; Research Personnel; Resolution; Resources; Sampling; Scheme; Services; Signal Transduction; Site; Speed; Study models; Techniques; Technology; Testing; Training; Translations; United States National Institutes of Health; Work; base; clinical translation; design; imaging modality; improved; in vivo; instrument; instrumentation; interest; magnetic field; magnetic resonance spectroscopic imaging; novel; phantom model; pre-clinical; preclinical study; programs; research study; success; technique development; technology development; temporal measurement; translation to humans; web site

PROJECT SUMMARY/ABSTRACT TR&D1 is responsible for the polarizer instrumentation and the MRI acquisition hardware/software required for all hyperpolarized 13C MRI studies performed in this P41 Center housing five dissolution DNP polarizers. All technology developments are driven by the 10 Collaborative Projects with iterative push-pull optimization and user training. These technology resources are then utilized by the 8 Service Projects (6 extramural) and the general scientific community with feedback on performance, quality of training, and ease of dissemination. In the inaugural funding cycle, TR&D1 oversaw new polarizer installation/development to enable and improve the hyperpolarizations required for all CP's and TR&D's, developed new MR sequences for preclinical studies driven by CP's and TR&D2 needs, and facilitated the first human clinical trial with recent preliminary translation work driven by the new CP's that include future clinical research (CP3,6,9,10). We have also worked closely with TR&D3 personnel to create and test new analysis methods to reconstruct, analyze and visualize the new HP 13C MRI techniques through this project. Also a major focus in the current and proposed renewal project is the training of new users (both intra- & extramural and facilitating the dissemination and widespread use of TR&D1 technology. Aim 1: Polarizer Instrumentation Development and Testing. In this aim new DNP/dissolution hardware and methods will be developed for Oxford Instruments HyperSense DNP polarizers, HyperSense Testbed polarizer, the POC polarizer used in the first Phase 1 Clinical Trial, and the GE SpinLab multi-sample polarizer. Aim 2: Preclinical HP 13C MRI Technology Development. In vivo hyperpolarized 13C MRI requires specialized hardware and MR sequences for optimal animal studies. Based on extensive preliminary work, Drs. Vigneron's and Larson's groups will develop specialized HP MR sequences optimized for performance, reliability, and ease of use in collaboration with preclinical CP1-8 investigators and Dr. Nelson TR&D3 analysis technique development group. Aim 3: New Acquisition Technology for Clinical Translation of HP 13C MRI. Driven by CP projects proposing human studies and with the input of the Translation Advisory Committee, new hardware/software will be developed to enable future novel HP 13C MRI clinical research studies with push-pull iterative optimization. This aim will also include training, dissemination, and input/feedback from SP3 and other sites proposing future patient HP 13C MRI.

项目概要/摘要 TR&D1 负责偏振器仪器和 MRI 采集所需的硬件/软件 所有超极化 13C MRI 研究均在配备五个溶解 DNP 偏振器的 P41 中心进行。全部 技术开发由 10 个协作项目推动，具有迭代推拉优化和 用户培训。这些技术资源随后被 8 个服务项目（6 个校外）和 一般科学界提供有关绩效、培训质量和传播便利性的反馈。在 在首个融资周期中，TR&D1 监督了新的偏光片安装/开发，以实现和改善 所有 CP 和 TR&D 所需的超极化，为临床前研究开发了新的 MR 序列 由 CP 和 TR&D2 需求驱动，并通过最近的初步翻译促进了首次人体临床试验 由新 CP 驱动的工作，包括未来的临床研究 (CP3、6、9、10)。我们也曾密切合作 与 TR&D3 人员一起创建和测试新的分析方法，以重建、分析和可视化新的 HP 13C MRI 技术通过该项目。当前和拟议的更新项目的一个主要重点是 新用户的培训（校内和校外，并促进传播和广泛使用 TR&D1 技术。 目标 1：偏振器仪器开发和测试。为了实现这一目标，新的 DNP/溶出硬件和 将为牛津仪器 HyperSense DNP 偏振器、HyperSense Testbed 偏振器、 首次一期临床试验中使用的 POC 偏光镜和 GE SpinLab 多样品偏光镜。 目标 2：临床前 HP 13C MRI 技术开发。体内超极化 13C MRI 需要专门的 用于最佳动物研究的硬件和 MR 序列。基于广泛的前期工作，博士。维涅龙的 Larson 的团队将开发专门的 HP MR 序列，针对性能、可靠性和 易于与临床前 CP1-8 研究人员和 Nelson 博士 TR&D3 分析技术合作使用 开发组。 目标 3：用于 HP 13C MRI 临床转化的新采集技术。在 CP 项目提议的推动下 人类研究和翻译咨询委员会的投入，新的硬件/软件将 旨在通过推拉迭代优化来实现未来新型 HP 13C MRI 临床研究。 这一目标还将包括培训、传播以及来自 SP3 和其他提出未来建议的站点的输入/反馈 患者 HP 13C MRI。